Litigation Details for ENCORE DERMATOLOGY INC. v. GLENMARK PHARMACEUTICALS LIMITED (D.N.J. 2020)

ENCORE DERMATOLOGY INC. v. GLENMARK PHARMACEUTICALS LIMITED (D.N.J. 2020)

Docket		Date Filed	2020-03-06
Court	District Court, D. New Jersey	Date Terminated	2022-04-04
Cause	35:271 Patent Infringement	Assigned To	Kevin McNulty
Jury Demand	None	Referred To	Edward S. Kiel
Patents	10,064,875; 9,855,334; 9,956,231
Link to Docket	External link to docket

Details for ENCORE DERMATOLOGY INC. v. GLENMARK PHARMACEUTICALS LIMITED (D.N.J. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2020-03-05	1	Complaint	Certification that the Claims of U.S. Patent Nos. 9,855,334, 9,956,231, and 10,064,875 are Invalid, Unenforceable…owns by assignment U.S. Patent No. 9,956,231 (the “’231 Patent”). The ’231 Patent was issued on May 1, … This is a civil action for patent infringement arising under the Patent Laws of the United States and…correct copy of the ’231 Patent is attached hereto as Exhibit C. The ’231 Patent expires on August 31, …or older. 24. The ’231 Patent, among other patents, is listed in the FDA’s Approved Drug	External link to document
2020-12-21	55	Opinion	owns U.S. Patent No. 9,956,231 (the “Patent”), which expires in 2030. (Compl. ¶ 17.) The Patent claims “…in a patent or the use of which is claimed in a patent before the expiration of such patent. 35 … has a patent for a topical pharmaceutical composition with the compound clobetasol. The patent also provides…any patents relate to the proposed drug. Id. Relevant here, the applicant may assert that a patent “will… drug claimed in a patent or the use of which is claimed in a patent . . . if the purpose	External link to document